Point72 Asset Management L.P. Grows Stock Holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Point72 Asset Management L.P. grew its holdings in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) by 26.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 3,426,599 shares of the company’s stock after purchasing an additional 710,936 shares during the period. Point72 Asset Management L.P.’s holdings in Centessa Pharmaceuticals were worth $57,396,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in CNTA. JPMorgan Chase & Co. raised its position in shares of Centessa Pharmaceuticals by 1,969.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 135,903 shares of the company’s stock worth $2,173,000 after purchasing an additional 129,335 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Centessa Pharmaceuticals by 39.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company’s stock worth $317,000 after buying an additional 5,316 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Centessa Pharmaceuticals by 14.4% in the fourth quarter. Wellington Management Group LLP now owns 115,107 shares of the company’s stock worth $1,928,000 after buying an additional 14,494 shares in the last quarter. Franklin Resources Inc. grew its holdings in shares of Centessa Pharmaceuticals by 0.3% during the fourth quarter. Franklin Resources Inc. now owns 2,308,546 shares of the company’s stock valued at $38,668,000 after buying an additional 6,000 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Centessa Pharmaceuticals by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 57,257 shares of the company’s stock valued at $959,000 after buying an additional 660 shares during the last quarter. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Centessa Pharmaceuticals news, insider David M. Chao sold 7,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $17.17, for a total transaction of $120,190.00. Following the transaction, the insider now owns 225,007 shares of the company’s stock, valued at $3,863,370.19. The trade was a 3.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Saurabh Saha sold 55,000 shares of the company’s stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $16.69, for a total transaction of $917,950.00. Following the completion of the transaction, the chief executive officer now owns 276,017 shares of the company’s stock, valued at approximately $4,606,723.73. The trade was a 16.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 171,398 shares of company stock worth $2,697,422 over the last quarter. 7.09% of the stock is currently owned by corporate insiders.

Centessa Pharmaceuticals Stock Performance

CNTA opened at $12.59 on Friday. Centessa Pharmaceuticals plc has a 12-month low of $7.75 and a 12-month high of $19.09. The company has a market cap of $1.68 billion, a price-to-earnings ratio of -8.23 and a beta of 1.53. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The company’s 50 day moving average is $13.56 and its 200 day moving average is $15.59.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.15. On average, equities research analysts predict that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Wall Street Analysts Forecast Growth

CNTA has been the topic of several analyst reports. Guggenheim reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Centessa Pharmaceuticals in a research report on Wednesday, March 26th. Piper Sandler initiated coverage on Centessa Pharmaceuticals in a report on Monday, March 31st. They set an “overweight” rating and a $38.00 price target on the stock. Oppenheimer started coverage on Centessa Pharmaceuticals in a report on Thursday, May 8th. They issued an “outperform” rating and a $6.00 price objective for the company. Morgan Stanley restated an “overweight” rating and set a $27.00 target price on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Finally, Chardan Capital began coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, May 8th. They set a “buy” rating and a $30.00 target price on the stock. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, Centessa Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $27.00.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.